Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions Monday July 8

Poster Groupings
Track A Drug Design and Discovery
AIDS Vaccine
Venue Palacio 4, level 8
Track B Diagnosis/Laboratory Monitoring
Provision and Evaluation of Care
Venue Palacio 4, level 7
Track C Descriptive Epidemiology
Venue Palacio 4, level 6
Track D Behavioral and Social Interventions
for Primary Prevention of HIV
Biomedical Interventions
Venue Palacio 4, level 5
Track E Social Analysis
Institutional Analysis
Venue Palacio 4, level 4
Track F HIV/AIDS Prevention
HIV/AIDS Impact Mitigation
Venue Palacio 4, level 3
Track G Funding, Resource Mobilization and Resource
Allocation
Capacity Development
Commitment and Accountability
Venue Palacio 4, level 2
MoPeA3ool Design and mechanism(s) of a novl HIV-Tat
antagonist - Neomycin B-arginine conjugate
A La idot, A Litovchick, A Kalinkovich, G Borkow
(Israel)
MoPeA3002 Identification of peptide ligands for the
packaging structure PSI (j) of HIV-1
A Pustowka M Landersz, I Dietz, U Dietrich
(Germany)
MoPeA300oo3 cDNA microarrays of host cell gene expression
during HIV-1 infection and with antiviral
treatment
P L Huang, L Zhang, P L Huang, S Lee-Huang
(United States)
MoPeA300oo4 Salvage therapy in patients with previous
evidence of M184V mutation
FMaggiolo. A Callegaro, G P Gregis, G P Quinzan,
CArici, D Ripamonti, A Goglio, F Suter (Italy)
MoPeA300oo5 Retrospective analysis of the use of Tenofovir DF
in a private practice
E Deesus, R Oritz, R TAnderson (United States)
MoPeA3oo6 Absence of residual viremia and resistance
associated mutations in HIV-infected patients
under highly active antiretroviral therapy
including non-nucloside analogues
R de la Rosa, A Rubio, M Leal, A Vallejo,
M Abad, E Ruiz-Mateos, R Asencio,
A Sdnchez-Quijano, E Lissen (Spain)
MoPeA3oo7 Uncoupling protein and brown adipocyte
mitochondria as potential targets of nucleoside
and non-nucleoside reverse transcriptase
inhibitor-induced lipodystrophy
M L Rodriguez de a Concepcion, R Iglesias,
P Yubero, I C Domingo, P Domingo, F Villarroya,
M Giralt (Spain)
MoPeA3oo8 Identification of the active metabolite of SPD-756
(BCH-1352o), a new purine analogue with potent
and selective activity against HIV-1
I M De Muys, I Lippens, B Hamelin, A Richard,
C Ren, P N Ba, R Bethell (Canada)
MoPeA3oo9 Simplified maintenance therapy with nevirapine:
efficacy in actual life

IDe la Torre I L Prada, A Del Arco, I Morales,
D Pefia, E Nufio (Spain)

MoPeA3olo Characterization of d4T and ddl resistance in
primary H IV strains from treated patients
M R Ferguson, ] J J von Lindern, X Han, D R Rojo,
L Shell, WA O'Brien (United States)
MoPeA3oll Differences in inhibitory concentrations (IC5o and
IC9o) of reverse transcriptase inhibitors between
tumour cell lines and normal lymphocytes
I Garcia-Perez, S Sanchez-Palomino, M Beltran,
J Alcami (Spain)
MoPeA3012 Highly active antiretroviral therapy (HAART):
comparing efficacy of protease inhibitor (PI)
based versus non-PI regimen
M Come na, Ossenkopp, M Sanchez, J Castro,
M E Marin, M A Guzman (Venezuela)
MoPeA3o13 Comparison of the efficacy, safety, and predictive
value of H IV genotyping using distinct ritonavirboosted protease inhibitors
P Barreiro, N Camino, C de Mendoza, M Nunez,
L Martin-Carbonero, J Gonzalez-Lahoz, V Soriano
(Spain)
MoPeA3o14 Ritonavir plus saquinavir versus single protease
inhibitor therapy in protease inhibitor-naive HIVinfected patients. The Swiss HIV Cohort Study
HC Bucher, P Taffe, H ]JFurrer, A Telenti,
B Hirschel, R Weber, E Bernasconi, P Vernazza,
C Minder, M Battegay, M Bichsel (Switzerland)
MoPeA3o15 Indinavir and nelfinavir pharmacokinetics in
patients with sustained virological response on
HAART, the cophar I - ANRS 102 study
C Goujard, M Legrand, FMentre, X Duval,
G Peytavin, B Diquet, A M Taburet (France)
MoPeA3o16 Superior virological efficacy of ritonavir-boosted
protease inhibitor regimens compared to single
protease inhibitor therapy
M Lichterfeld, A Wdhrmann, N Schmeisser,
G Faetkenheuer, T Sauerbruch, J K Rockstroh
(Germany)
MoPeA3o17 Salvage treatment with lopinavir/ritonavir
(Kaletra) in HIV-infected patients failing all
current antiretroviral drug families
C de Mendoza (Spain)
MoPeA3o18 The HIV protease dimer interface and GagPol
processing
A H Kaplan, L Everitt, S Choudhury, S C Pettit
(United States)
MoPeA3o19 Dynamics of HIV Replication in T Lymphocytes
M Bermeo., L Usdn, I Alcami (Spain)
MoPeA3o2o Effect of combination antiretroviral therapy based
on indinavir or nevirapine on peripheral blood
lymphocyte apoptosis
P Domingo, MA Sambeat, JA Arroyo, M JCarnice, A
Fontanet, FX Nomdedeu, J A Arroyo,
J Cadafalch, I Orellana, M Gurgui, G Vazquez (Spain)
MoPeA3o21 A diketoacid integrase inhibitor potentiates the
antiviral and anti-integrase activities of L-chicoric
acid, a dicaffeoyltartaric acid
D Lee, I G Victoria, B R McDougall,
WE Robinson, ir. (United States)
MoPeA3o22 An HIV-1 Fusion Inhibitor Disrupting the gp41 SixHelix Bundle Formation
Sliang, Q Zhao, I T Ernst, A D Hamilton,
A K Debnath (United States)
MoPeA3o23 Porphyrins with high virucidal activity for HIV-1
A N Vzorov, D W Dixon, IS Trommel, L G Marzilli,
R W Compans (United States)
MoPeA3o24 HIV-1 gp41 variability in a cohort of Spanish patients

M T Cuevas M L Villahermosa, R Carmona,
L Pdrez-Alvarez, L Medrano, M M Thomson,
E Vdzquez de Parga, E Delgado, M Sierra,
L Cuevas, R Ndjera (Spain)
XIV International AIDS Conference BARCELONA- JULY 7-12

Monday

31